Alexandru Vlagea1, Dora Pascual-Salcedo2, Rita Álvarez Doforno2, Paz Lavilla3, Jesús Diez4, Beatriz Padilla Merlano2, María V Cuesta5, Antonio Gil3. 1. Immunology Department, Hospital Clinic, Barcelona, Spain; Immunology Department, Hospital La Paz, Madrid, Spain. Electronic address: vlagea@clinic.cat. 2. Immunology Department, Hospital La Paz, Madrid, Spain. 3. Internal Medicine Department, Hospital La Paz, Madrid, Spain. 4. Department of Biostatistics in Medicine, Hospital La Paz, Madrid, Spain. 5. Hematology Department, Hospital La Paz, Madrid, Spain.
Abstract
OBJECTIVE: IgG and IgM antibodies directed at β2-glycoprotein I are included in the classification criteria for the antiphospholipid syndrome (APS) while the IgA antibodies against β2-glycoprotein I (IgA aβ2GPI) are not. Conflicting data about the significance of IgA aβ2GPI and APS manifestation can be found and more studies are necessary in order to define the diagnostic value of IgA aβ2GPI. In the present article, we investigated the possible role of IgA aβ2GPI as marker of APS. METHODS: A cohort of 314 patients with APS and systemic autoimmune disease was investigated for the presence of IgA aβ2GPI and its association with clinical manifestation of APS. RESULTS: Eighty-nine patients presented IgA aβ2GPI, 68 cases associated with others antiphospholipid antibodies (aPL) and in 21 cases being the only aPL present. In primary APS IgA aβ2GPI are highly coincidental with other aPL (92,2%) while most of the isolated IgA aβ2GPI were present in the SLE group (16/21). No association between IgA aβ2GPI and APS manifestations: thrombosis and pregnancy morbidity was found, while a positive association between IgA aβ2GPI and the presence of anti-nDNA, anti-RNP, anti-Sm, anti-SSA, anti-SSB antibodies was encountered. CONCLUSION: Our study does not show association between IgA aβ2GPI and APS manifestations and does not support the inclusion of IgA aβ2GPI as a classification criteria for APS.
OBJECTIVE: IgG and IgM antibodies directed at β2-glycoprotein I are included in the classification criteria for the antiphospholipid syndrome (APS) while the IgA antibodies against β2-glycoprotein I (IgA aβ2GPI) are not. Conflicting data about the significance of IgA aβ2GPI and APS manifestation can be found and more studies are necessary in order to define the diagnostic value of IgA aβ2GPI. In the present article, we investigated the possible role of IgA aβ2GPI as marker of APS. METHODS: A cohort of 314 patients with APS and systemic autoimmune disease was investigated for the presence of IgA aβ2GPI and its association with clinical manifestation of APS. RESULTS: Eighty-nine patients presented IgA aβ2GPI, 68 cases associated with others antiphospholipid antibodies (aPL) and in 21 cases being the only aPL present. In primary APS IgA aβ2GPI are highly coincidental with other aPL (92,2%) while most of the isolated IgA aβ2GPI were present in the SLE group (16/21). No association between IgA aβ2GPI and APS manifestations: thrombosis and pregnancy morbidity was found, while a positive association between IgA aβ2GPI and the presence of anti-nDNA, anti-RNP, anti-Sm, anti-SSA, anti-SSB antibodies was encountered. CONCLUSION: Our study does not show association between IgA aβ2GPI and APS manifestations and does not support the inclusion of IgA aβ2GPI as a classification criteria for APS.
Authors: Medha Barbhaiya; Stephane Zuily; Yasaman Ahmadzadeh; Mary-Carmen Amigo; Tadej Avcin; Maria Laura Bertolaccini; D Ware Branch; Guilherme de Jesus; Katrien M J Devreese; Camille Frances; David Garcia; Francis Guillemin; Steven R Levine; Roger A Levy; Michael D Lockshin; Thomas L Ortel; Surya V Seshan; Maria Tektonidou; Denis Wahl; Rohan Willis; Ray Naden; Karen Costenbader; Doruk Erkan Journal: Arthritis Care Res (Hoboken) Date: 2021-09-02 Impact factor: 5.178
Authors: Oscar Cabrera-Marante; Edgard Rodríguez de Frías; Manuel Serrano; Fernando Lozano Morillo; Laura Naranjo; Francisco J Gil-Etayo; Estela Paz-Artal; Daniel E Pleguezuelo; Antonio Serrano Journal: Int J Mol Sci Date: 2020-11-26 Impact factor: 5.923
Authors: Pavla Bradacova; Ludek Slavik; Jana Ulehlova; Adela Skoumalova; Jana Ullrychova; Jana Prochazkova; Antonin Hlusi; Gayane Manukyan; Eva Kriegova Journal: Biomedicines Date: 2021-02-08